Shares of Aptevo Therapeutics (NASDAQ:APVO) have earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $10.50 for the company and are forecasting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aptevo Therapeutics an industry rank of 150 out of 265 based on the ratings given to its competitors.
Several equities analysts recently weighed in on APVO shares. Roth Capital started coverage on Aptevo Therapeutics in a research note on Wednesday, April 11th. They issued a “buy” rating and a $12.00 price target for the company. ValuEngine upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Piper Jaffray lifted their price objective on Aptevo Therapeutics from $6.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, May 10th.
In related news, insider Marvin L. White sold 100,000 shares of Aptevo Therapeutics stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $2.93, for a total value of $293,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in Aptevo Therapeutics by 11.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,219,852 shares of the biotechnology company’s stock worth $3,989,000 after buying an additional 123,236 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Aptevo Therapeutics by 411.8% in the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock worth $1,816,000 after buying an additional 344,700 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Aptevo Therapeutics by 346.6% in the 1st quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock worth $832,000 after buying an additional 197,341 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Aptevo Therapeutics by 10.3% in the 1st quarter. Victory Capital Management Inc. now owns 215,110 shares of the biotechnology company’s stock worth $703,000 after buying an additional 20,000 shares during the last quarter. Finally, Alambic Investment Management L.P. acquired a new stake in Aptevo Therapeutics in the 1st quarter worth about $646,000. Institutional investors own 32.89% of the company’s stock.
Shares of Aptevo Therapeutics stock traded down $0.27 on Monday, hitting $5.67. The company’s stock had a trading volume of 306,642 shares, compared to its average volume of 210,190. The company has a quick ratio of 5.08, a current ratio of 4.47 and a debt-to-equity ratio of 0.20. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $6.35. The firm has a market cap of $134.16 million, a PE ratio of -3.71 and a beta of 0.40.
Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.07). Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 47.64%. The business had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $3.37 million. sell-side analysts expect that Aptevo Therapeutics will post -2.14 EPS for the current year.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.